BriaCell Therapeutics Analyst Ratings
BriaCell Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a reiterated with a price target of $0.00 to $25.00. The current price BriaCell Therapeutics (BCTX) is trading at is $7.21, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/24/2023 | 246.74% | HC Wainwright & Co. | → $25 | Reiterates | → Buy |
| 02/14/2022 | 246.74% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 02/24/2023 | 246.74% | HC Wainwright公司 | →$25 | 重申 | →购买 |
| 02/14/2022 | 246.74% | HC Wainwright公司 | →$25 | 开始承保 | →购买 |
What is the target price for BriaCell Therapeutics (BCTX)?
Briacell治疗公司(BCTX)的目标价格是多少？
The latest price target for BriaCell Therapeutics (NASDAQ: BCTX) was reported by HC Wainwright & Co. on February 24, 2023. The analyst firm set a price target for $25.00 expecting BCTX to rise to within 12 months (a possible 246.74% upside). 1 analyst firms have reported ratings in the last year.
Briacell治疗公司(纳斯达克代码：BCTX)的最新目标价是由HC Wainwright&Co.于2023年2月24日报道的。这家分析公司将目标价定为25美元，预计BCTX将在12个月内上涨(可能上涨246.74%)。1家分析公司在过去一年公布了评级。
What is the most recent analyst rating for BriaCell Therapeutics (BCTX)?
Briacell治疗公司(BCTX)的最新分析师评级是什么？
The latest analyst rating for BriaCell Therapeutics (NASDAQ: BCTX) was provided by HC Wainwright & Co., and BriaCell Therapeutics reiterated their buy rating.
BriaCell治疗公司(纳斯达克代码：BCTX)的最新分析师评级由HC Wainwright&Co.提供，Briacell治疗公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for BriaCell Therapeutics (BCTX)?
Briacell治疗公司(BCTX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BriaCell Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BriaCell Therapeutics was filed on February 24, 2023 so you should expect the next rating to be made available sometime around February 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与BriaCell Treeutics的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Briacell治疗公司的上一次评级是在2023年2月24日提交的，所以你应该预计下一次评级将在2024年2月24日左右提供。
Is the Analyst Rating BriaCell Therapeutics (BCTX) correct?
分析师对Briacell Treeutics(BCTX)的评级正确吗？
While ratings are subjective and will change, the latest BriaCell Therapeutics (BCTX) rating was a reiterated with a price target of $0.00 to $25.00. The current price BriaCell Therapeutics (BCTX) is trading at is $7.21, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Briacell治疗公司(BCTX)评级被重申，目标价在0.00美元至25.00美元之间。BriaCell Treateutics(BCTX)目前的交易价格为7.21美元，在分析师的预测范围内。
